RYTM

Rhythm Pharmaceuticals, Inc. Common Stock

93.52

USD

RYTM Earnings Reports

Positive Surprise Ratio

RYTM beat 18 of 34 last estimates.

53%

Next Report

Date of Next Report

May 05, 2026

Estimate for Q1 26 (Revenue/ EPS)

$57.87M

-$0.84

Implied change from Q4 25 (Revenue/ EPS)

+1.08%

+15.07%

Implied change from Q1 25 (Revenue/ EPS)

+76.95%

+3.70%

Rhythm Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Jan 09, 2026, RYTM reported earnings of -0.73 USD per share (EPS) for Q4 25, beating the estimate of -0.83 USD, resulting in a 12.89% surprise. Revenue reached 57.25 million, compared to an expected 56.12 million, with a 2.02% difference. The market reacted with a +3.83% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 12 analysts forecast an EPS of -0.84 USD, with revenue projected to reach 57.87 million USD, implying an increase of 15.07% EPS, and increase of 1.08% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Liquidia Corporation Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

$0.18

Actual

$0.15

Surprise

-18.48%

EyePoint, Inc. Common Stock

Report Date

Mar 04, 2026 For Q4 25

Estimate

-$0.76

Actual

-$0.81

Surprise

-6.20%

Kura Oncology, Inc.

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.62

Actual

-$0.92

Surprise

-47.84%

CorMedix Inc.

Report Date

Mar 05, 2026 For Q4 25

Estimate

$0.83

Actual

$0.61

Surprise

-26.73%

REGENXBIO Inc.

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.97

Actual

-$1.30

Surprise

-33.31%

Lexicon Pharmaceuticals, Inc.

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.07

Actual

-$0.04

Surprise

+43.18%

Contineum Therapeutics, Inc. Class A Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.41

Actual

-$0.49

Surprise

-18.41%

Lineage Cell Therapeutics, Inc.

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.05

Actual

$0.00

Surprise

+100.00%

Atea Pharmaceuticals, Inc. Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$0.54

Actual

-$0.56

Surprise

-5.44%

Aligos Therapeutics, Inc. Common Stock

Report Date

Mar 05, 2026 For Q4 25

Estimate

-$1.88

Actual

-$1.91

Surprise

-1.11%

FAQ

What were Rhythm Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Rhythm Pharmaceuticals, Inc. Common Stock reported EPS of -$0.73, beating estimates by 12.89%, and revenue of $57.25M, 2.02% above expectations.

How did the market react to Rhythm Pharmaceuticals, Inc. Common Stock's Q4 2025 earnings?

The stock price moved up 3.83%, changed from $101.02 before the earnings release to $104.89 the day after.

When is Rhythm Pharmaceuticals, Inc. Common Stock expected to report next?

The next earning report is scheduled for May 05, 2026.

What are the forecasts for Rhythm Pharmaceuticals, Inc. Common Stock's next earnings report?

Based on 12 analysts, Rhythm Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.84 and revenue of $57.87M for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.